Dr. Kubassova and IAG’s Bio-Partnering are Attending Bio International, June 3-6, 2019 in Philadelphia USA.
Dr. Olga Kubassova, CEO of IAG and Venture Partner at Analytics Ventures and Bio Capital Impact Fund will be attending Bio, Philadelphia, USA together with bio-partnering team of IAG. Dr. Kubassova will also be a part of the investment panel to discuss challenges and opportunities for the lifescience industry in the US and China, topics around industry trends and cross-border opportunities between US and China. Given the increasing need for collaboration in therapy development, Dr. Kubassova will introduce IAG’s technology-enabled, risk-sharing and mitigation partnerships, and targeted development strategies.
IAG’s Bio-Partnering team is an independent investment division of IAG that is building a diversified investment portfolio of innovative life science companies at various stages of clinical development, with first partnerships including immuno-oncology, neuro-oncology and immunology focused partners. At the Bio meeting, IAG team seeks to engage with companies and discuss the development of clinical stage assets, IP acquisition from the academic partners and biotech companies, investment partnerships and strategic collaborations.
To find out more about IAG’s Bio-Partnering services or to schedule a meeting during BIO 2019 please send an email to email@example.com
About BIO 2019
The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. The conference brings together businesses, investors and academics and runs over 500 education sessions and netwrokign events, click here.
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed, www.ia-grp.com